CRX.L Regulatory News (CRX)

23 Nov 2007 13:50

Cyprotex PLC23 November 2007 The Director/PDMR Shareholding announcement released on 23 November 2007 at09.49 under RNS 3663I has the following amendment: In the last line, the figure 0.16% has now been changed to 1.16% to avoid any confusion. The full amended text is shown below. Press Release 23 November 2007 Cyprotex PLC ("Cyprotex" or "the Company") Director share purchases Cyprotex PLC (AIM: CRX), the drug discovery technology and information companywas notified today that Robert Morrison Atwater, the Chairman and ChiefExecutive of the Company purchased a total of 175,000 ordinary shares of 0.1peach in the Company on 22 November 2007 at the following price per share: 75,000shares at 3.74p; 50,000 shares at 3.78p; and 50,000 shares at 4.00p. RobertMorrisson Atwater now has a total interest of 1,610,000 ordinary shares in theCompany, which represents 1.16% of the issued share capital of the Company. - Ends - For further information: Cyprotex PLCMark Warburton Tel: +44 (0) 1625 505100iir@cyprotex.com www.cyprotex.com This information is provided by RNS The company news service from the London Stock Exchange